# Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride

> **NCT01944774** · PHASE2 · COMPLETED · sponsor: **TaiGen Biotechnology Co., Ltd.** · enrollment: 207 (actual)

## Conditions studied

- Pneumonia

## Interventions

- **DRUG:** Nemonoxacin 500 mg
- **DRUG:** Nemonoxacin 650 mg
- **DRUG:** Moxifloxacin 400 mg

## Key facts

- **NCT ID:** NCT01944774
- **Lead sponsor:** TaiGen Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01944774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01944774, "Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01944774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*